- Home
- COCH vs LIXT Comparison
COCH vs LIXT Comparison
Compare COCH & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- LIXT
- Stock Information
- Founded
- COCH 1995
- LIXT 2005
- Country
- COCH United States
- LIXT United States
- Employees
- COCH N/A
- LIXT N/A
- Industry
- COCH Blank Checks
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- COCH Finance
- LIXT Health Care
- Exchange
- COCH Nasdaq
- LIXT Nasdaq
- Market Cap
- COCH 25.2M
- LIXT 24.4M
- IPO Year
- COCH N/A
- LIXT N/A
- Fundamental
- Price
- COCH $1.47
- LIXT $4.89
- Analyst Decision
- COCH Strong Buy
- LIXT
- Analyst Count
- COCH 2
- LIXT 0
- Target Price
- COCH $9.25
- LIXT N/A
- AVG Volume (30 Days)
- COCH 7.4M
- LIXT 184.3K
- Earning Date
- COCH 11-13-2025
- LIXT 11-11-2025
- Dividend Yield
- COCH N/A
- LIXT N/A
- EPS Growth
- COCH N/A
- LIXT N/A
- EPS
- COCH N/A
- LIXT N/A
- Revenue
- COCH $222,000.00
- LIXT N/A
- Revenue This Year
- COCH $4.27
- LIXT N/A
- Revenue Next Year
- COCH $23.37
- LIXT N/A
- P/E Ratio
- COCH N/A
- LIXT N/A
- Revenue Growth
- COCH N/A
- LIXT N/A
- 52 Week Low
- COCH $0.74
- LIXT $0.64
- 52 Week High
- COCH $3.41
- LIXT $6.26
- Technical
- Relative Strength Index (RSI)
- COCH 69.25
- LIXT 50.85
- Support Level
- COCH $0.74
- LIXT $4.64
- Resistance Level
- COCH $0.85
- LIXT $5.53
- Average True Range (ATR)
- COCH 0.13
- LIXT 0.48
- MACD
- COCH 0.04
- LIXT -0.08
- Stochastic Oscillator
- COCH 70.42
- LIXT 17.89
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.